Search Medical Condition
Please enter condition
Please choose location from dropdown

Ankylosing Spondylitis Clinical Trials

A listing of Ankylosing Spondylitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (53) clinical trials

Prediction of Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive SpA

The general prevalence of spondyloarthritis (SpA) is 0.5% of the Caucasian population and that of ankylosing spondylitis (AS) is 0.3% in France. First-line treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) is insufficiently effective in more than half of AS patients in hospitals. These patients are then treated with "anti-tumor necrosis factor ...

Phase N/A

Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)

The purpose of this study is to determine if tofacitinib is safe and effective in subjects with active ankylosing spondylitis.

Phase

One-year Persistence to Treatment of Participants Receiving Flixabi: a French Cohort Study

A study to describe the one-year persistence (participants still treated by Flixabi at 12 Months) in participants treated by Flixabi (infliximab) as prescribed by the physician for each of the 5 following indications: Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Crohn's Disease (CD) [adults and children] and Ulcerative ...

Phase N/A

Treat-to-target With Secukinumab in Axial Spondyloarthritis

Comparison of reductions in MRI inflammation in the sacroiliac joints and spine from week 16 to 24 in patients who at week 16 are in ASDAS remission (i.e. continue sc. secukinumab 150 mg monthly) vs. not in ASDAS remission (i.e. increase sc. secukinumab 300 mg monthly). ASDAS remission is defined ...

Phase

Sequential Application of Yisaipu and DMARDs in Treating Mild-to-Moderate AS

The drug regimes in treating ankylosing spondylitis(AS) have limitations. The tumor necrosis factor inhibitors(TNFi) was effective but expensive. Disease modifying anti-rheumatic drugs (DMARDs) were cheap but insufficient. This study proposed a sequential usage of TNFi, the Yisaipu, and DMARDs, and aims to evaluate the mid-term therapeutic effect of this new ...

Phase

Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases

The objective of this study is to evaluate the effect of adalimumab on health outcomes in participants with rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis.

Phase N/A

Fertility Study of Women With Chronic Inflammatory Rheumatism

Data collection will be carried out using a questionnaire submitted to women in charge of the rheumatology department of the University Hospital of Toulouse and having agreed to participate women with Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis or Chronic juvenile arthritis for the chronic inflammatory rheumatism group women with a ...

Phase N/A

Investigating the Use of Salaso to Improve Physiotherapy Management of Ankylosing Spondylitis (AS).

AS is a chronic inflammatory condition affecting the spine and other joints, causing pain and stiffness. Currently approximately 150 people attend Saint James's Hospital rheumatology department for management of their condition. Physiotherapy plays a key role in this management. As this is often a younger patient population, it can be ...

Phase N/A

Function Locomotion Measurement and Inflammation

This longitudinal cohort study is aiming to follow 60 persons with ankylosing spondylitis during 18 months. Assessments will be conducted at baseline and every 6 months. An healthy control group of 30 persons will be included and age and sex matched to the first 30 patients.

Phase N/A

A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis

This post-marketing study will evaluate safety and efficacy profile of golimumab (a fully human anti-Tumour Necrosis Factor alpha [TNF-alpha] monoclonal antibodies [mAb], administered subcutaneously) in a real-world in Indian participants with active spondyloarthropathy of ankylosing spondylitis (AS) or psoriatic arthritis (PsA). AS is a chronic inflammatory disease of unknown etiology ...

Phase